FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report
This article was originally published in The Gray Sheet
The agency made subtle but potentially notable changes from a draft in its final five-year strategic priorities document, released Sept. 30.
You may also be interested in...
“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Medtech Insight spoke to the chief executive and chief operating officers of Plenity’s manufacturer, Gelesis, to learn more about its weight loss device.